News last week including US biotechs Alumis and Acelyrin announcing that they are merging to create a late-stage clinical ...

Marking World Cancer Day 2025, this week's Executive Q&A is with Diego Santoro, General Manager & Head of International ...

The US Food and Drug Administration (FDA) has issued several warning letters to pharmaceutical manufacturers in India and ...

Regeneron Pharmaceuticals today announced financial results for the fourth quarter and full year 2024 and provided a business ...

Danish pharma major Novo Nordisk has announced interim results from the Phase III FRONTIER3 trial of 70 children with ...

Biotech firm CSL Behring has announced the four-year results from the pivotal HOPE-B study confirming the long-term ...

Roche has reported positive results from its Phase III REGENCY trial of Gazyva (obinutuzumab) for the treatment of lupus ...

Alumis (Nasdaq: ALMS) and Acelyrin (Nasdaq: SLRN) have agreed to merge in an all-stock deal, creating a late-stage ...

Shares of rare disease drug developer X4 Pharmaceuticals took a battering after it said it will restructure its workforce and ...

US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from ...

Lundbeck’s total revenue grew by +14% at constant exchange rates (CER) and 11% in kroner terms to 22,004 million kroner ...

Netherlands-based Bilthoven Biologicals, the Dutch subsidiary of the Serum Institute of India and a leading end-to-end ...